Register 

Choose Your Preferred Publication
  • White Facebook Icon
  • Shaun Bateman

Dupilumab lowers some infection rates in moderate to severe atopic dermatitis

Dupilumab decreased the risk for serious or severe infection and

nonherpetic skin infections in patients with moderate to severe atopic

dermatitis compared with placebo, according to results published in

the American Journal of Clinical Dermatology.


“In this pooled analysis, dupilumab- and placebo-treated patients did not

significantly differ in their rates of overall infections or discontinuation due

to infections, whereas serious or severe infections, skin infections and

clinically important herpesviral infections (eczema herpeticum or herpes

zoster) occurred at lower rates in the dupilumab groups than in the placebo

group,” Lawrence F. Eichenfield, MD, of the departments of dermatology

and pediatrics at the University of California, San Diego, and the division of

pediatric and adolescent dermatology at Rady Children’s Hospital in San

Diego, and colleagues wrote.


Of 2,932 patients with moderate to severe atopic dermatitis, 1,091 patients

were randomly assigned to placebo, 1,095 to dupilumab (Dupixent,

Regeneron/Sanofi) 300 mg weekly and 746 to dupilumab 300 mg every 2

weeks.


Dupilumab decreased the risk for serious or severe infections (number of

patients per 100 person-years RR = 0.43; 95% CI, 0.22-0.85) compared

with placebo, as well as bacterial and other nonherpetic skin infections

(number of patients per 100 person-years RR = 0.44; 95% CI, .029-0.66),

the researchers reported. However, the dupilumab treatment groups had

similar infection rates overall per 100 patient-years and similar nonskin

infection rates.


Additionally, the use of systemic anti-infective medication was lower with

dupilumab compared with placebo, they wrote.


“Although herpesviral infection rates overall were slightly higher with

dupilumab than placebo, clinically important herpesviral infections (eczema


herpeticum, herpes zoster) were less common with dupilumab (RR =

0.31; P < .01),” the researchers wrote. – by Monica Jaramillo


SOURCE: https://www.healio.com/dermatology/dermatitis/news/online/%7B96c1c5f8-b57f-4a3d-b223-26d44df44001%7D/dupilumab-lowers-some-infection-rates-in-moderate-to-severe-atopic-dermatitis

0 views
  • Med Suite Media Instagram Icon
  • Med Suite Media Facebook
  • Med Suite Media LinkedIn Icon
  • Med Suite Media Twitter
  • SA Media & Digital HoldingsYouTube